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1. Mutant gene banks from human hCNT1 cDNA and hCNT1 cDNA derived non-
functional E497Q-hCNT1 molecule (for technical control purpose; E497Q-hCNT1 
construction is described in section 2) were constructed and used for screening of 
gain-of-function mutants.  
 The primary goal was to develop a mosaic patterned partial mutant gene bank 
from human hCNT1 (O00337) cDNA. According to the suggestions of the reviewers the 
experimental approach to select small parts of the cDNA molecule for intensive 
mutagenesis had been changed for in silico analysis approach. Altogether 14 sections of 
hCNT1 cDNA were selected for mutagenesis. The flanking sequences were to be left 
native. First we tested the critical technical process, the development of the mosaic 
patterned molecule. Primers for the PCR amplification of 2x14 cDNA sections were 
designed to be overlapped with the neighbouring primer by 10 nucleotides. Assembly of 
the complete cDNA molecule by Stemmer's in vitro recombination process (Stemmer 
1994 PNAS 91:10747-10751) from their 28 sections has been attempted several times 
without success. Besides the 1:1 molecule ratio of the purified template molecules, 
several ratios different from 1:1 were repeated without success. Further we focused on 
the development of the mutant gene bank by a more conventional approach. Here the 
entire cDNA molecule was subjected to random mutagenesis through error-prone PCR, 
and then the mutations were combined by subsequent repetition of Stemmer's in vitro 
reassembly process. Besides the hCNT1 cDNA molecule we also carried out the 
procedure on a non-functional mutant molecule, E497Q-hCNT1 cDNA (construction is 
described at section 2) for the purpose of using the mutant gene bank of E497Q-hCNT1 
cDNA for the technical evaluation of the carried out process. Due to a random 
mutagenesis a backmutation event is expected on the non-functional E497Q-hCNT1 
molecule that results in the formation of a functional molecule that could be isolated 
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when the E497Q-hCNT1 mutant gene bank is transformed into cntA::riboB pyrG89 
pantoB100 riboB2 pyrG89 A. nidulans strain. During the development of hCNT1 and 
E497Q-hCNT1 mutant gene banks error-prone PCR was carried out by five consecutive 
repetitions where products of a previous PCR were used as template in the following 
reaction. The series of error prone PCRs were followed by three consecutive repetitions 
of Stemmer's in vitro molecule disassembly/assembly procedure that resulted the random 
combination of the primary mutations. Mutant gene banks were finally constructed by the 
transformation of the mutated molecule populations of hCNT1 and E497Q-hCNT1 into 
pNNPanto expression vector (development of the vector is described in section 4). The 
quality of the mutant gene banks were monitored by restriction analysis of 250 
independent clones. The quality of the hCNT1 mutant gene bank was assessed to be 
satisfactory. Two transformations and direct selections were carried out with A. nidulans 
strains uapA24 uapC201/401 azgA4 pantoB100 (uptake deficient for hypoxanthine and 
uric acid) and furA::riboB pantoB100 yA2 riboB2 (uptake deficient for allantoin) 
(development of strains are described in section 6) without resulting a gain-of-function 
mutant. The mutant gene bank of E497Q-hCNT1 was transformed into cntA::riboB 
pyrG89 pantoB100 riboB2 strain and 2 transformants were isolated on uridine 
supplemented minimal media. The appearance of two transformants clearly indicated that 
the process of mutant gene bank construction was technically correct. Probably the gene 
bank was not rich in mutants. Regardless, it is worth to repeat the transformation 
processes in case of hCNT1 mutant gene bank. In any case, the existing hCNT1 mutant 
molecule population can be subjected to further series of mutagenesis processes and a 
more extensively mutated gene bank can be developed for the isolation of gain-of-
function mutants.  
 
2. A non-functional E497Q-hCNT1 mutant hCNT1 cDNA molecule was constructed 
by directed point mutagenesis for the purpose of generation and using the E497Q-
hCNT1 mutant gene bank to evaluate technically the process of mutant gene bank 
generation.  
 The main purpose of generating a point-mutant non-functional hCNT1 molecule 
was to track the steps of mutant gene bank construction and in case of failure of the 
application of hCNT1 mutant gene bank, the technical failures can be detected or 
excluded. The G (Guanine) in position of 1489 in the cDNA had been changed to C 
(Cytosine) by PCR based directed mutagenesis that resulted the change of glutamate (E) 
to glutamine (Q) at the residue 497 in the hCNT1 molecule. The generated E497Q-
hCNT1 molecule is expected to fail to be expressed at the surface of the cell membrane 
that results uridine uptake deficiency. The E497Q-hCNT1 molecule was transformed into 
cntA::riboB pyrG89 pantoB100 riboB2 pyrG89 A. nidulans (description of mutant 
construction is described in section 3) and transformants were not detected. To 
complement the pyrG89 mutation the cntA::riboB pyrG89 pantoB100 riboB2 pyrG89 
strain needs to take up extracellular uridine by an active transporter. When the E497Q-
hCNT1 is subjected to random mutagenesis, and a mutant gene bank is generated, then it 
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is expected to detect back-mutants where the native nucleotide is reestablished at position 
1489 that results a functional uridine carrier transporter. A back mutant can be isolated by 
transformation of cntA::riboB pyrG89 pantoB100 riboB2 pyrG89 strain and by selection 
on uridine supplemented minimal media. 
 
3. cntA::riboB pyrG89 pantoB100 riboB2 A. nidulans deletion mutant was developed 
by crossing cntA::riboB pyrG89 pyroA4 biA1 riboB2 with pantoB100 riboB2 for the 
purpose of test-transformation of (i) hCNT1 and E497Q-hCNT1 in the heterologue 
expression system; (ii) transformation with E497Q-hCNT1 mutant gene bank. 
 The cntA::riboB pyrG89 pantoB100 riboB2 A. nidulans deletion mutant was 
developed by crossing cntA::riboB pyrG89 pyroA4 biA1 riboB2 (Hamari et al. 2009 Mol. 
Microbiol. 73: 43-57) strain with pantoB100 riboB2 mutant. The developed cntA::riboB 
pyrG89 pantoB100 riboB2 strain meets the demand of testing the heterologue expression 
of hCNT1 and E497Q-hCNT1 cloned into pNNPanto expression vector (vector 
construction and test transformation are described in section 4 and 5, respectively); and 
the requirements needed for transformation with E497Q-hCNT1 mutant gene bank. This 
strain is not able to grow on uridine and pantothenic acid supplemented media unless a 
functional uridine transporter is expressed the strain. (To complement the pyrG89 
mutation the cntA::riboB pyrG89 pantoB100 riboB2 pyrG89 strain needs to take up 
extracellular uridine by an active transporter.)  
 
4. Novel autonomous expression vector of A. nidulans, pNNPanto was developed by 
engineering the existing pAnGFP integrative GFP fusion A. nidulans vector in four 
steps.  
 The integrative E. coli based A. nidulans expression vector pAnGFP (Pokorska et 
al. 2000 J.Mol.Biol.298:585-596) was reengineered to achieve an autonomous 
replicative, pantoB markered expression vector that support the generation of mutant 
gene banks and the transformation of suitable A. nidulans recipient strains (see sections 3 
and 6). The following reengineering processes were carried out on the original pAnGFP 
vector: the amaI replication origo sequence was inserted, pantoB selection marker 
sequence was inserted, GFP coding region was eliminated and the flanking Pgpd 
constitutive promoter and trpC termination seqences were kept and NdeI/NotI cloning 
sites were built in between them; the single native NdeI site of the original vector had 
been disrupted by cloning the pantoB marker sequence onto blunt-ended NdeI site. The 
constructed pNNPanto expression vector was 13.2 kb in size (Karácsony and Hamari 
2010, poster presentation at the annual conference of Hungarian Society of 
Microbiologists at 2010 October, Keszthely, Hungary). 
 
5. Heterologous expression of the human hCNT1 and E497Q-hCNT1 and the 
expression of A. nidulans CntA (AN5493.3) cDNAs cloned in pNNPanto autonomous 
expression vector were carried out in cntA::riboB pyrG89 pantoB100 riboB2 
recipient strain. 
 The cntA::riboB pyrG89 pantoB100 riboB2 strain is not able to produce uridine 
endogenously due to the pyrG89 mutation and deficient in extracellularly available 
uridine uptake due to the deletion of the gene for the executive uridine transporter, cnt. 
When hCNT1 cDNA cloned in pNNPanto vector had been transformed into this recipient 
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strain, transformant colonies could be isolated. By plasmid rescue process it was 
demonstrated that all of the transformants carried the hCNT1 expression vector and the 
hCNT1 produced a functionally active transporter. By transformation of the same 
recipient strain with E497Q-hCNT1 cDNA cloned in pNNPanto we confirmed that the 
E497Q-hCNT1 mutant molecule is deficient in the uptake of uridine. The expression 
vector itself was tested and evaluated by cloning and expressing the native uridine 
transporter of A. nidulans (CNT) in the recipient cntA::riboB pyrG89 pantoB100 riboB2 
strain.  
 
6. Hypoxanthine/uric acid and allantoin uptake deficient mutants were developed 
for the purpose of direct screening for gain-of-function mutants.  
 For the screening of hypoxanthine/uric acid gain-of-function mutants uapA24 
uapC201/401 azgA4 pantoB100 strain was developed by cross of uapA24 uapC201/401 
azgA4 pabaA1 strain with pantoB100 riboB2 mutant. 
For the screening of allantoin gain-of-function mutants the furA::riboB pantoB100 yA2 
riboB2 strain was available as a result of our previous work on transporters (Hamari et al. 
2009 Mol. Microbiol. 73: 43-57).  
 
 
